Published: Thu, February 01, 2018
Sports | By Toni Houston

Sanofi to acquire biopharma company Ablynx

Sanofi to acquire biopharma company Ablynx

Brandicourt said caplacizumab would complement Sanofi's line-up of blood products, following the acquisition of Bioverativ and an earlier deal to obtain global rights for fitusiran from Alnylam.

Sanofi chief executive Olivier Brandicourt said the decision to acquire Ablynx came after a successful existing partnership with the Belgian company, adding that the deal will help the group to "continue to advance the transformation of our R&D pipeline and strengthening our platform for growth in rare blood disorders".

Ablynx also has an inhaled anti-RSV Nanobody in its portfolio, called ALX-0171, which is being developed for the symptomatic treatment of RSV infections.

The company has around 45 proprietary and partnered programmes with AbbVie, Boehringer Ingelheim, Eddingpharm, Novartis, Merck & Co, Novo Nordisk, Sanofi and others in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. ALX-0171 would be "very" complementary to Sanofi Pasteur RSV associated programs, according to the buyer.

Eight of these nanobodies have entered clinical development, with Sanofi committed to accelerating development and maximising the commercial potential of these programmes.

BBC Women: We have experienced 'veiled threats' over equal pay queries
Yet it confidently asserts there is "no evidence" of gender bias in pay decisions, merely some "anomalies that need addressing". The BBC's China editor, Carrie Gracie , quit this month to protest what she called a failure to address the pay gap.

The two firms had already been partnered up to find new treatments in inflammatory diseases since a year ago.

Sanofi has agreed a deal to acquire Ablynx, a biopharmaceutical company engaged in the discovery and development of nanobody therapies. Both the Sanofi and Ablynx boards have approved the deal. "Our Board of Directors feels strongly that this transaction represents compelling value for shareholders and maximizes the potential of our pipeline to the benefit of all stakeholders".

Sanofi has offered some €45 per share for Ablynx, representing a valuation of around €3.9 billion.

Sanofi said that while it expected the addition of Ablynx would increase the long-term value of the company to shareholders by adding to its pipeline of drugs under development, research expenses would mean no increased earnings per share this year or in 2019. We are also pleased to reaffirm our commitment to Belgium, where we have invested significantly over the years in our state-of-the-art biologics manufacturing facility in Geel.

Like this: